PSP - Unmatched sepsis biomarker

Pancreatic Stone Protein

PSP will become No. 1 biomarker for the early detection of sepsis.

Sepsis

Number 1 killer in hospitals

Serious infections, also referred to as severe sepsis, are among leading causes of death in intensive care units (ICUs) and thus pose a major challenge to health care workers. Sepsis is a syndrome characterized by an overwhelming systemic response to infection, which can rapidly lead to vital organ dysfunction, cardiovascular collapse, irreversible multiple organ failure and death. Severe sepsis accounts for 40% of total ICU expenditure. Every year, 18 million individuals die from severe sepsis. In the United States alone, the estimate of cases, a decade ago, was 750’000 per year. This number will likely reach 1 million this year, and despite tremendous research, increasing efforts, and therapeutic progresses, mortality rates from sepsis remain disappointingly high, ranging between 30% and 50% of sepsis cases.

PSP assay

Early diagnosis save lives

Early diagnosis is crucial to improve the outcome of patient care and increase survival rates. LASCCO developed a new biomarker, the Pancreatic Stone Protein (PSP), for the prediction of sepsis outcome. The test allows early detection of sepsis, several days before onset. PSP blood levels tightly correlate with severity and risk. This important prognostic information could improve rapid risk stratification, lead to the optimization of treatments for severely ill patients, help clinicians to allocate more accurately hospital resources and ICU beds and cut down on the unnecessary use of antibiotics.

Latest News

LASCCO’s partner Abionic launches first Covid-19 Severity Test to triage patients quickly and accurately, based on PSP
November 26, 2020

More information

Selected publications

Klein HJ, et al. Pancreatic Stone Protein Predicts Sepsis in Severely Burned Patients Irrespective of Trauma Severity: A Monocentric Observational Study. Ann Surg. 2020; 10.1097

Klein HJ, et al.. Expression of Pancreatic Stone Protein is Unaffected by Trauma and Subsequent Surgery in Burn Patients. World J Surg. 2020; 44(9):3000-3009.

García de Guadiana-Romualdo L, et al. Prognostic performance of pancreatic stone protein in critically ill patients with sepsis. Biomark Med. 2019; 13(17):1469-1480

Eggimann P, et al. Measurement of pancreatic stone protein in the identification and management of sepsis. Biomark Med. 2019; 13(2):135-145.

Que YA, et al. Prognostication of mortality in critically ill patients with severe infections. Chest 2015; 148(3):674-82.

Klein HJ, et al. Pancreatic stone protein predicts postoperative infection in cardiac surgery patients irrespective of cardiopulmonary bypass or surgical technique. PLoS One 2015; 10(3):e0120276.

Llewelyn MJ, et al. Sepsis biomarkers in unselected patients on admission to intensive or high-dependency care. Critical Care 2013; 17, R60.

Gukasjan R, et al. Pancreatic Stone Protein Predicts Outcome in Patients With Peritonitis in the ICU. Critical Care Med. 2013; 41(4):1027-36.

Schlapbach LJ, et al. Pancreatic stone protein as a novel marker for neonatal sepsis. Intensive Care Med. 2013; 39(4):754-63

Que YA, et al. Pancreatic stone protein as an early biomarker predicting mortality in a prospective cohort of patients with sepsis requiring ICU management. Critical Care 2012; 16, R114.

Boeck L, et al. Pancreatic stone protein: a marker of organ failure and outcome in ventilator-associated pneumonia. Chest 2001; 140(4):925-932.

Keel M, et al. Pancreatic stone protein is highly increased during posttraumatic sepsis and activates neutrophil granulocytes. Critical Care Medicine 2009; 37, 1642–1648.